Αρχική World News Exceptional Response to Single-Agent Anti-PD1 Therapy Observed in Patients with Advanced Desmoplastic... World News Exceptional Response to Single-Agent Anti-PD1 Therapy Observed in Patients with Advanced Desmoplastic Melanoma Από Ogkologos - 4 Σεπτεμβρίου, 2025 818 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SWOG S1512 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR EMA Recommends Granting a Marketing Authorisation for Akeega, Fixed-Dose Combinations of... 10 Μαρτίου, 2023 ESMO contributes to discussions on the future of cancer care at... 7 Οκτωβρίου, 2026 Apalutamide Plus ADT Demonstrates a Rapid, Deep, and Durable PSA Decline... 29 Μαρτίου, 2023 FDA Approves Imlunestrant for ER-positive, HER2-negative, ESR1-mutated Advanced or Metastatic Breast... 10 Οκτωβρίου, 2025 Φόρτωση περισσοτέρων HOT NEWS ΚΑΡΚΙΝΟΣ ΕΝΔΟΜΗΤΡΙΟΥ Study Suggests Some Arthritis Drugs May Actually Stop the Spread of... Adding Autologous Stem-Cell Transplantation to Triplet Treatment, Followed by Lenalidomide Maintenance... Zantac Contains A Cancer-Causing Chemical And Now Breast Cancer Patients Are...